IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

IDEAYA Biosciences (NASDAQ: IDYA) announced on February 26, 2026 that its Compensation Committee granted non-qualified stock options to purchase 346,200 shares to three newly hired employees as inducement awards under the 2023 Inducement Plan pursuant to Nasdaq Rule 5635(c)(4).

The options carry an exercise price of $31.90 (closing price on grant date), a 10-year term, and vest over four years (25% at year one, then monthly over three years), subject to continued service.

Key Figures

Inducement options granted: 346,200 shares Option exercise price: $31.90 per share Option term: 10 years +3 more

6 metrics

Inducement options granted 346,200 shares Non-qualified stock options to three new employees

Option exercise price $31.90 per share Equal to closing price on grant date

Option term 10 years Term of inducement stock options

Vesting period 4 years 25% at year one, remainder monthly over three years

Initial vesting tranche 25% Vests on first anniversary of vesting commencement date

Current share price $31.90 Matches option exercise price and latest close

Market Reality Check

Price: $32.20 Vol: Volume 788,743 vs 20-day ...

normal vol

$32.20 Last Close

Volume Volume 788,743 vs 20-day average 856,848 shares (relative volume 0.92x). normal

Technical Trading above 200-day MA, with price at $31.90 vs 200-day MA of $27.86.

Peers on Argus

Peers showed mixed moves: DNLI (-3.51%), GLPG (-0.45% in sector list but +1.37% ...

1 Up

Peers showed mixed moves: DNLI (-3.51%), GLPG (-0.45% in sector list but +1.37% in momentum scan), BLTE (+0.43%), FOLD (-0.07%), TVTX (+1.26%). Only GLPG appeared in the momentum scanner, supporting a stock-specific context for IDYA.

Historical Context

5 past events · Latest: Feb 25 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 25	Clinical trial update	Positive	-1.3%	First-patient-in for IDE034 Phase 1 trial with milestone payment.
Feb 23	Management change	Positive	+0.4%	Appointment of experienced Chief Development Officer for R&D strategy.
Feb 17	Earnings and update	Positive	+1.6%	Q4 and FY25 results with strong cash position and pipeline progress.
Feb 02	Investor outreach	Positive	+5.8%	Participation in virtual investor events with senior leadership.
Jan 30	Inducement grants	Neutral	-2.4%	Inducement stock options grant of 44,200 shares under 2023 plan.

Pattern Detected

Recent news has generally seen modest price reactions, with one clinical milestone drawing a negative move despite positive implications.

Recent Company History

Over recent months, IDEAYA reported several milestones, including a Phase 1 first‑patient‑in for IDE034 on Feb 25, 2026 and the appointment of a new Chief Development Officer on Feb 23, 2026. Financial results on Feb 17, 2026 highlighted $1.05 billion in cash and multiple advancing programs. The company also announced investor event participation and prior inducement grants (44,200 options at $32.99) on Jan 29, 2026. Today’s inducement grants continue that pattern of equity-based hiring activity.

Market Pulse Summary

This announcement details routine inducement equity grants: 346,200 non-qualified stock options at a...

Analysis

This announcement details routine inducement equity grants: 346,200 non-qualified stock options at an exercise price of $31.90, vesting over four years with a standard 25% cliff. It continues IDEAYA’s use of its 2023 Inducement Plan to attract new talent, following a similar grant on Jan 29, 2026. Investors may track how expanding headcount supports advancing programs highlighted in recent earnings and regulatory filings, while monitoring future updates on clinical progress and capital allocation.

Key Terms

non-qualified stock options, nasdaq listing rule 5635(c)(4), exercise price

3 terms

non-qualified stock options financial

"granted non-qualified stock options to purchase an aggregate of 346,200 shares"

Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.

nasdaq listing rule 5635(c)(4) regulatory

"as an inducement material ... in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

exercise price financial

"The stock options have an exercise price of $31.90 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

AI-generated analysis. Not financial advice.

SOUTH SAN FRANCISCO, Calif., Feb. 27, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on February 26, 2026, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 346,200 shares of the Company's common stock to three newly hired employees. The stock options were granted under the IDEAYA Biosciences, Inc. 2023 Employment Inducement Incentive Award Plan (2023 Inducement Plan) as an inducement material to such individuals' entering into employment with IDEAYA in accordance with Nasdaq Listing Rule 5635(c)(4).

The 2023 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of IDEAYA, or following a bona fide period of non-employment, as an inducement material to such individuals' entering into employment with IDEAYA, pursuant to Nasdaq Listing Rule 5635(c)(4).

The stock options have an exercise price of $31.90 per share, which is equal to the closing price of IDEAYA's common stock on The Nasdaq Global Select Market on the date of grant. The stock options have a 10-year term and will vest over four years, with 25% of the options vesting on the first anniversary of the vesting commencement date and the remaining 75% of the options vesting in equal monthly installments over the three years thereafter. Vesting of the stock options is subject to such employee's continued service to IDEAYA on each vesting date.

About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer. Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease. We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates, or ADCs, for molecularly defined solid tumor indications. Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective, and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer.

Investor and Media Contact
IDEAYA Biosciences
Joshua Bleharski, Ph.D.
Chief Financial Officer 
investor@ideayabio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302699240.html

SOURCE IDEAYA Biosciences, Inc.

FAQ

How many shares did IDEAYA (IDYA) grant as inducement awards on February 26, 2026?

IDEAYA granted options to purchase 346,200 shares as inducement awards to three new hires. According to the company, these grants were made under the 2023 Inducement Plan as material inducements under Nasdaq Listing Rule 5635(c)(4).

What is the exercise price and term of the IDEAYA (IDYA) inducement stock options?

The stock options have an exercise price of $31.90 and a 10-year term. According to the company, $31.90 equals IDEAYA's closing Nasdaq price on the February 26, 2026 grant date.

What is the vesting schedule for the inducement options granted by IDEAYA (IDYA)?

The options vest over four years: 25% at the first anniversary, then the remaining 75% monthly over three years. According to the company, vesting is conditioned on each employee's continued service on each vesting date.

Under which plan were IDEAYA's (IDYA) February 26, 2026 inducement awards granted?

The awards were granted under the 2023 Inducement Plan, used exclusively for new-employee inducement equity awards. According to the company, the plan complies with Nasdaq Listing Rule 5635(c)(4) requirements.

Will the IDEAYA (IDYA) inducement grants dilute existing shareholders materially?

The announcement discloses 346,200 shares of option awards but does not state total shares outstanding or dilution percentage. According to the company, the grants were issued as standard inducement awards under Nasdaq rules.

Who received the inducement option grants from IDEAYA (IDYA) and why were they granted?

Three newly hired employees received the options as material inducements to join IDEAYA. According to the company, the grants were part of hiring compensation under the 2023 Inducement Plan in compliance with Nasdaq rules.